TRACON Pharmaceuticals, Inc. (TCON)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 3.67 Million | -26.23 Million | -22.57 Million | -17.04 Million | -23.65 Million | -30.78 Million |
| Net Income | -3.58 Million | -29.13 Million | -28.66 Million | -16.77 Million | -22.67 Million | -34.95 Million |
| Depreciation & Amortization | 14 Thousand | 70 Thousand | -59 Thousand | -13 Thousand | 16 Thousand | 28 Thousand |
| Deferred income taxes | -3.38 Million | - | -1000.00 | -1000.00 | -52 Thousand | -100 Thousand |
| Stock-based compensation | 1.96 Million | 2.04 Million | 1.77 Million | 1.03 Million | 1.62 Million | 2.66 Million |
| Change in working capital | -2.15 Million | -239 Thousand | 4.54 Million | -1.57 Million | -2.87 Million | 4.2 Million |
| Other non-cash items | 10.82 Million | 1.02 Million | -164 Thousand | 292 Thousand | 315 Thousand | -2.62 Million |
| Investing Cash Flow | - | -17 Thousand | 3.95 Million | -4 Million | 14.02 Million | -8.86 Million |
| Investments in PPE | - | -17 Thousand | -48 Thousand | -5000.00 | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | -3.99 Million | -4.98 Million | -32.86 Million |
| Sales/Maturities of investments | - | - | 4 Million | - | 19 Million | 24 Million |
| Other Investing Activities | - | - | 4 Million | -3.99 Million | 14.02 Million | -8.86 Million |
| Financing Cash Flow | -12.53 Million | 19.68 Million | 10.56 Million | 36.76 Million | 906 Thousand | 35.32 Million |
| Debt repayment | -20.5 Million | -1.68 Million | -2.8 Million | -1.4 Million | -1.4 Million | -8.32 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 7.96 Million | 7.87 Million | 13.36 Million | 38.16 Million | 2.29 Million | 36.45 Million |
| Other Financing Activities | 7.96 Million | 13.48 Million | 13.36 Million | 2000.00 | 12 Thousand | 7.18 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -1.39 Million | -233 Thousand | 4.68 Million | -1.87 Million | -3.42 Million | 4.14 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | -761 Thousand | -6000.00 | -138 Thousand | 299 Thousand | 542 Thousand | 62 Thousand |
| Cash at beginning of period | 17.43 Million | 24.07 Million | 32.13 Million | 16.41 Million | 25.13 Million | 29.46 Million |
| Cash at end of period | 8.56 Million | 17.5 Million | 24.07 Million | 32.13 Million | 16.41 Million | 25.13 Million |
| Capital Expenditure | - | -17 Thousand | -48 Thousand | -5000.00 | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -8.86 Million | -6.57 Million | -8.05 Million | 15.71 Million | -8.72 Million | -4.33 Million |
| Free Cash Flow | 3.67 Million | -26.25 Million | -22.61 Million | -17.04 Million | -23.65 Million | -30.78 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -2.83 Million | -3.16 Million | 439 Thousand | -3.58 Million | 10.76 Million | -6.28 Million |
| Depreciation & Amortization | 4000.00 | 4000.00 | 3000.00 | 14 Thousand | 8000.00 | 8000.00 |
| Deferred income taxes | - | - | 617 Thousand | -3.38 Million | - | - |
| Stock-based compensation | 339 Thousand | 383 Thousand | 490 Thousand | 1.96 Million | 493 Thousand | 502 Thousand |
| Change in working capital | -273 Thousand | 234 Thousand | -1.45 Million | -2.15 Million | 3.11 Million | -5.6 Million |
| Other non-cash items | - | 163 Thousand | -613 Thousand | 10.82 Million | 669 Thousand | 5.53 Million |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 1.14 Million | 1.87 Million | 1.32 Million | -12.53 Million | -9.09 Million | 1.04 Million |
| Debt repayment | - | - | -20.5 Million | -20.5 Million | -10.5 Million | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 1.14 Million | 1.87 Million | 1.32 Million | 7.96 Million | 1.4 Million | 1 Million |
| Other Financing Activities | 1000.00 | 1.87 Million | 20.5 Million | 7.96 Million | 1.4 Million | 43 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -546 Thousand | 232 Thousand | -856 Thousand | -1.39 Million | -5.6 Million | 3.92 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | 273 Thousand | 2000.00 | -602 Thousand | -761 Thousand | 8.72 Million | -9.53 Million |
| Cash at beginning of period | 7.96 Million | 8.56 Million | 7.76 Million | 17.43 Million | 1.87 Million | 6.67 Million |
| Cash at end of period | 6.34 Million | 7.89 Million | 8.56 Million | 8.56 Million | 7.83 Million | 1.87 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -1.62 Million | -673 Thousand | 801 Thousand | -8.86 Million | 5.96 Million | -4.8 Million |
| Free Cash Flow | -2.76 Million | -2.54 Million | -522 Thousand | 3.67 Million | 15.05 Million | -5.85 Million |
9246
ASGLF
1912
BACHY
9955
ACGLN